The analysis of the effectiveness and safety of levofloxacin in the treatment of lower respiratory tract infection.

Loading...
Thumbnail Image
Date
2015
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective of the current study was to investigate the effectiveness and safety of levofloxacin in the treatment of lower respiratory tract infection. The study was carried out in hospital on 120 patients with lower respiratory tract infection from January 2014 to January 2015. Patients were randomly divided into control and observation groups, each group contained 60 patients. The control group was given the routine dose of levofloxacin, whereas the observation group received the high dose of levofloxacin. The clinical effectiveness and incidence rate of untoward reactions between the two groups were statistically analyzed and evaluated. Patients’ cure rate in the observation group was 53.33%, significantly higher than that of the control group which was only 36.67%. Their differences have statistical significance (P<0.05). Observation group demonstrated a very good total effective rate of 93.33%, compared to the control group (78.33%). Their differences have statistical significance (P<0.05). Incidence of adverse reactions in case of both the observation and control group patients, were relatively low, resulting insignificant statistical difference between the groups (P>0.05). This study shows better clinical curative effect of high doses of levofloxacin treating lower respiratory infection with minimum risk. This method, which can significantly improve the quality of patient treatment with low adverse reaction risk, is worth popularizing in clinical use.
Description
Keywords
lower respiratory tract infection, levofloxacin, effectiveness, safety analysis
Citation
Alreshidi Ibrahim Dughaim, Al-Mutairi Khalid Mohammed, Han Xie. The analysis of the effectiveness and safety of levofloxacin in the treatment of lower respiratory tract infection. International Current Pharmaceutical Journal. 2015; 4(12): 462-464.